A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

We support the overall FDA process for evaluating new antihyperglycemic drugs, which requires adequate data to demonstrate efficacy in lowering blood glucose and to provide reasonable assurance of ...

They found uptake of cardioprotective antihyperglycemic drugs—including glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors—increased over the 10-year study ...

When compared to DPP-4 inhibitors, this drug class reduced the risk by four for every 1,000 PY. Our research suggested that GLP-1 agonists were associated with a lower risk of dementia compared to ...

As experience with these novel antihyperglycemic drugs increases, future studies with longer follow-up periods should be conducted to corroborate our findings. Patients were followed from cohort ...

In comparison with a low-fat diet, a Mediterranean-style, low-carbohydrate diet delays the need for antihyperglycemic drug therapy in overweight patients with type 2 diabetes mellitus (T2DM).

GLP-1RAs are antihyperglycemic agents with protective ... GLP-1RAs would positively help physicians prescribe this class of drug for treatment. The current study used a discovery approach to ...